Fagron, the leading global player in pharmaceutical compounding, announces the successful completion of its acquisition of Vepakum in Latin America. The transaction, announced in December 2025, was ...

Rapid results for ADHD, Anxiety and OCD: Improves executive function and lessens the din of unwelcome thoughts. Calms the overactive amygdala to assist patients in processing trauma free of physical ...

SNIPR also provided a clinical update on its ongoing Phase 1b trial of SNIPR001 in patients with hematological cancer undergoing hematopoietic stem-cell transplantation (HSCT). Recruitment in this ...

MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the pricing of its ...

Peters brings over 15 years of senior care and financial expertise to advance Care@Home 4 Life's mission of keeping seniors safely in the homes they love. Miami, FL, March 02, 2026 (GLOBE NEWSWIRE) -- ...

J.P. Morgan is acting as the underwriter for the offering.

Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received ...

Format: Fireside Chat and 1x1 Investor Meetings Date/Time: Monday, March 9, 2026, from 3:40 – 4:10 pm ET The presentation will be webcast live and archived in the Investor Relations section of ...

An archived replay of the webcast will be available on the Tenaya website for approximately 30 days following the conference. About Tenaya Therapeutics Tenaya Therapeutics is a clinical-stage ...

Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility own ...

Konik Capital Partners LLC, a division of T.R. Winston & Company, is acting as the sole book-running manager for the offering. MAIA intends to use the net proceeds from the offering to conduct ...

The Precise MRD test is Myriad’s tumor-informed circulating tumor DNA (ctDNA) assay designed to support longitudinal monitoring during cancer treatment. Using whole-genome sequencing to create a ...